olprinone has been researched along with Cardiovascular Stroke in 8 studies
olprinone: RN refers to HCl; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors examined whether olprinone, a phosphodiesterase type 3 inhibitor, or isoflurane, a volatile anesthetic, could protect the heart against myocardial infarction in type 2 diabetic rats and whether the underlying mechanisms involve protein kinase C (PKC), mitochondrial ATP-sensitive potassium (m-K(ATP)) channels, or the phosphatidylinositol 3-kinase (PI3K)-Akt pathway." | 3.75 | Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway. ( Cho, S; Hara, T; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S; Ureshino, H, 2009) |
| "05), which was significantly improved by treatment with high dosage of olprinone (dp/dt max: 1348." | 1.51 | Effect of olprinone on ischemia-reperfusion induced myocardial injury in rats. ( Han, MX; Lu, SQ; Xu, XW; Zhang, GX, 2019) |
| "Olprinone was very effective for improving ventricular dysfunction; its institution prior to induction of anesthesia made successful anesthetic management possible without resorting to a mechanical assist device like the intra-aortic balloon pump." | 1.32 | [Successful anesthetic management of patients with poor ventricular function using the phosphodiesterase III inhibitor, olprinone, during major cardiovascular procedures]. ( Bougaki, M; Chang, KH; Hanaoka, K; Ogawa, M; Sugano, T, 2004) |
| "Olprinone was also examined with an intracoronary cotreatment with a PKA inhibitor (H89), a PKC inhibitor (GF109203X), an extracellular signal-regulated kinase kinase (MEK) inhibitor (PD98059), or a p38 MAPK inhibitor (SB203580) throughout the preischemic period." | 1.31 | Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. ( Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, MX | 1 |
| Xu, XW | 1 |
| Lu, SQ | 1 |
| Zhang, GX | 1 |
| Matsumoto, S | 2 |
| Cho, S | 2 |
| Tosaka, S | 2 |
| Ureshino, H | 1 |
| Maekawa, T | 2 |
| Hara, T | 1 |
| Sumikawa, K | 2 |
| Tosaka, R | 1 |
| Nomura, Y | 1 |
| Horimoto, H | 1 |
| Mieno, S | 1 |
| Nakahara, K | 1 |
| Okawa, H | 1 |
| Yoshida, M | 1 |
| Shinjiro, S | 1 |
| Chang, KH | 1 |
| Ogawa, M | 1 |
| Bougaki, M | 1 |
| Sugano, T | 1 |
| Hanaoka, K | 1 |
| Arai, T | 1 |
| Cho, T | 1 |
| Enomoto, S | 1 |
| Ichiki, A | 1 |
| Kase, S | 1 |
| Sato, E | 1 |
| Tsuchida, M | 1 |
| Kuno, Y | 1 |
| Inoue, H | 1 |
| Okuda, Y | 1 |
| Takaoka, H | 1 |
| Takeuchi, M | 1 |
| Hata, K | 1 |
| Hayashi, Y | 1 |
| Mori, M | 1 |
| Yamakawa, H | 1 |
| Yamaguchi, K | 1 |
| Yokoyama, M | 1 |
| Sanada, S | 1 |
| Kitakaze, M | 1 |
| Papst, PJ | 1 |
| Asanuma, H | 1 |
| Node, K | 1 |
| Takashima, S | 1 |
| Asakura, M | 1 |
| Ogita, H | 1 |
| Liao, Y | 1 |
| Sakata, Y | 1 |
| Ogai, A | 1 |
| Fukushima, T | 1 |
| Yamada, J | 1 |
| Shinozaki, Y | 1 |
| Kuzuya, T | 1 |
| Mori, H | 1 |
| Terada, N | 1 |
| Hori, M | 1 |
8 other studies available for olprinone and Cardiovascular Stroke
| Article | Year |
|---|---|
Effect of olprinone on ischemia-reperfusion induced myocardial injury in rats.
Topics: Animals; Autophagy; Beclin-1; Coronary Vessels; Heart; Imidazoles; Male; Myocardial Infarction; Myoc | 2019 |
Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.
Topics: Anesthetics, Inhalation; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Imidaz | 2009 |
Roles of cyclooxygenase 2 in sevoflurane- and olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts.
Topics: Animals; Cardiotonic Agents; Coronary Vessels; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Heart; | 2011 |
Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Coronary Circulation; Cyclic AMP; Cyclic AMP-Dependent | 2003 |
[Successful anesthetic management of patients with poor ventricular function using the phosphodiesterase III inhibitor, olprinone, during major cardiovascular procedures].
Topics: Aged; Anesthesia, General; Angina, Unstable; Aortic Aneurysm, Abdominal; Aortic Rupture; Blood Vesse | 2004 |
[Successful anesthetic management of three patients with cardiac dysfunction for non-cardiac surgery using olprinone hydrochloride].
Topics: Aged; Anesthesia, Inhalation; Cardiomyopathy, Dilated; Cardiotonic Agents; Humans; Imidazoles; Male; | 2005 |
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.
Topics: Cardiac Output; Cardiotonic Agents; Dobutamine; Dose-Response Relationship, Drug; Hemodynamics; Huma | 1997 |
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-D | 2001 |